Paolo Tarantino: How do SONIA and NATALEE impact our use of CDK4/6-inhibitors

Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:

“How do SONIA and NATALEE impact our use of CDK4/6-inhibitors? Should they still be given 1L? And are we ready for adjuvant ribociclib? Glad to join my friend and former co-fellow Albert Grinshpun for reviewing updates in the CDK4/6i field on ASCO Daily News.”

Additional information.

Source: Paolo Tarantino/X